Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:CDT NASDAQ:PCSA NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.52$0.52$0.52▼$29.97$1.42MN/A5.06 million shsN/ACDTCDT Equity$0.55-5.8%$1.50$0.54▼$586.00$2.67M1.443.55 million shs273,375 shsPCSAHeatwurx$1.92-1.0%$2.53$1.76▼$14.24$5.32M162,178 shs26,441 shsSNGXSoligenix$0.40+0.5%$0.58$0.28▼$6.23$5.96M1.833.91 million shs54,974 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro0.00%0.00%0.00%0.00%-91.75%CDTCDT Equity-8.33%-61.13%-43.94%-88.57%-99.90%PCSAHeatwurx+4.30%-6.73%-24.22%-23.32%-60.45%SNGXSoligenix-2.44%+2.56%-56.04%-66.10%-70.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.52$0.52$0.52▼$29.97$1.42MN/A5.06 million shsN/ACDTCDT Equity$0.55-5.8%$1.50$0.54▼$586.00$2.67M1.443.55 million shs273,375 shsPCSAHeatwurx$1.92-1.0%$2.53$1.76▼$14.24$5.32M162,178 shs26,441 shsSNGXSoligenix$0.40+0.5%$0.58$0.28▼$6.23$5.96M1.833.91 million shs54,974 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro0.00%0.00%0.00%0.00%-91.75%CDTCDT Equity-8.33%-61.13%-43.94%-88.57%-99.90%PCSAHeatwurx+4.30%-6.73%-24.22%-23.32%-60.45%SNGXSoligenix-2.44%+2.56%-56.04%-66.10%-70.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 1.50ReduceN/AN/ACDTCDT Equity 1.00SellN/AN/APCSAHeatwurx 2.00Hold$25.001,202.08% UpsideSNGXSoligenix 2.00Hold$6.001,392.54% UpsideCurrent Analyst Ratings BreakdownLatest ABP, SNGX, CDT, and PCSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026CDTCDT Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PCSAHeatwurx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SNGXSoligenix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbproN/AN/AN/AN/A($8.83) per shareN/ACDTCDT EquityN/AN/AN/AN/A($77.82) per shareN/APCSAHeatwurxN/AN/AN/AN/A$2.46 per shareN/ASNGXSoligenixN/AN/AN/AN/A$0.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23M-$4.23N/AN/AN/AN/AN/A-344.76%N/ACDTCDT Equity-$39.22M-$66,338.55N/AN/AN/AN/A-4,263.33%-529.91%N/APCSAHeatwurx-$13.56M-$9.29N/AN/AN/AN/A-281.31%-200.80%8/6/2026 (Estimated)SNGXSoligenix-$11.08M-$1.68N/AN/AN/AN/A-244.73%-131.22%8/13/2026 (Estimated)Latest ABP, SNGX, CDT, and PCSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026SNGXSoligenix-$0.30-$0.28+$0.02-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/ACDTCDT EquityN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.070.07CDTCDT EquityN/A0.340.34PCSAHeatwurxN/A0.980.98SNGXSoligenixN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%CDTCDT Equity3.29%PCSAHeatwurx91.93%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipABPAbpro13.70%CDTCDT Equity10.78%PCSAHeatwurx3.50%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro152.72 million2.34 millionN/ACDTCDT Equity34.86 million4.33 millionNot OptionablePCSAHeatwurx202.77 million2.67 millionNot OptionableSNGXSoligenix2014.82 million14.37 millionNot OptionableABP, SNGX, CDT, and PCSA HeadlinesRecent News About These CompaniesSoligenix Expands At-the-Market Equity Offering CapacityJune 26, 2026 | tipranks.comSoligenix Inc. (NASDAQ:SNGX) Short Interest Down 92.6% in JuneJune 26, 2026 | americanbankingnews.comSoligenix Applying for Vaccine Development Funding for Bundibugyo Ebola VaccineJune 8, 2026 | prnewswire.comSoligenix Expands At-The-Market Equity Financing CapacityMay 28, 2026 | tipranks.comSNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail FrenzyMay 27, 2026 | finance.yahoo.comSuitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in CongoMay 26, 2026 | prnewswire.comSOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial ResultsMay 8, 2026 | finanznachrichten.deSoligenix Announces Recent Updates and First Quarter 2026 Financial ResultsMay 8, 2026 | prnewswire.comSNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatmentApril 29, 2026 | msn.comSNGX phase 3 trial halted on HyBryteApril 29, 2026 | msn.comSOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell LymphomaApril 28, 2026 | finanznachrichten.deSNGX phase 3 trial halted — HyBryte setback puts strategy in questionApril 28, 2026 | msn.comSoligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell LymphomaApril 28, 2026 | prnewswire.comSoligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation ApproachApril 23, 2026 | finance.yahoo.comSoligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation ApproachApril 23, 2026 | usatoday.comSoligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan StatusApril 20, 2026 | financial-news.co.ukSoligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan StatusApril 20, 2026 | finance.yahoo.comSoligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study ResultsApril 17, 2026 | financial-news.co.ukSoligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study ResultsApril 17, 2026 | finance.yahoo.comSoligenix (SNGX) price target decreased by 14.29% to 15.30April 15, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABP, SNGX, CDT, and PCSA Company DescriptionsAbpro NASDAQ:ABP$0.52 0.00 (0.00%) As of 06/26/2026Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.CDT Equity NASDAQ:CDT$0.55 -0.03 (-5.83%) As of 11:40 AM Eastern This is a fair market value price provided by Massive. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Heatwurx NASDAQ:PCSA$1.92 -0.02 (-1.03%) As of 11:34 AM Eastern This is a fair market value price provided by Massive. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.Soligenix NASDAQ:SNGX$0.40 +0.00 (+0.50%) As of 11:39 AM Eastern This is a fair market value price provided by Massive. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Achieves Escape Velocity With Nasdaq Fast-Track 3 Top Financial Institutions Announce Over $70 Billion in Share Repurchases Rezolve AI Stock Has a Short-Squeeze Setup, But Execution Comes First The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
